We are proud to share the news that GESSEL has once again been noted in the Legal 500 international ranking of law firms.

Dr Beata Gessel-Kalinowska vel Kalisz was named as a Leading Individual in the Dispute Resolution category.

Also recommended are the GESSEL lawyers:

Our firm received recommendations in the following categories:

  • Commercial, Corporate and M&A
  • Dispute Resolution
  • Tax
  • Private Equity

We are especially happy to note the testimonials about our firm and our professionals:

GESSEL Attorneys at Law handles both advisory and transactional work for a variety of local and foreign corporates. The group is led by Marcin Macieszczak, who advised Bioton on the sale of a 95.6% stake in SciGen to the China-based Yifan International Pharmaceutical. Highlights for Maciej Kożuchowski included acting for Polski Bank Komórek Macierzystych on the acquisition of a majority stake in the Portuguese-listed company Stemlab. Małgorzata Badowska and Aldona Pietrzak are also recommended.

GESSEL Attorneys at Law's team is 'distinguished' in the field of arbitration, drawing partly on the expertise of Beata Gessel-Kalinowska vel Kalisz, who is a member of the ICC International Court of Arbitration in Paris. Highlights for Gessel-Kalinowska vel Kalisz included representing a Polish joint-stock company as the claimant in a dispute with a seller before a Polish court of arbitration. Managing associate Natalia Jodłowska is another key name.

GESSEL Attorneys at Law has a strong transactional tax practice, and a team that regularly assists corporates involved in M&A and restructuring. Department head Janusz Fiszer is assisting Esche Schümann Commichau as local counsel with the possible tax treatment of the Polish employee of a German manufacturer operating in Poland.

Private equity is a key component of GESSEL Attorneys at Law's practice. The team is led by managing partner Marcin Macieszczak, who primarily specialises in public and private equity transactions. Maciej Kożuchowski advised Polski Bank Komórek Macierzystych on its acquisition of a majority stake in Portugal-based Stemlab.